[{"orgOrder":0,"company":"Hepion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anti-Fibrotic Activity of Hepion Pharmaceuticals\u2019 CRV431 Shows Potential to Extend to Multiple Organs and Fibrotic Diseases","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Hepion Pharmaceuticals"},{"orgOrder":0,"company":"MAX BioPharma","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MAX BioPharma Announces Key Update to its Liver Fibrosis Program ","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"MAX BioPharma"},{"orgOrder":0,"company":"Acquist Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acquist Therapeutics Expands Patent Portfolio for Novel Small Molecules, Receives Fourth U.S. Composition Patent","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Acquist Therapeutics"},{"orgOrder":0,"company":"Lamassu Pharma","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$1.5 million","upfrontCash":"Undisclosed","newsHeadline":"Lamassu Pharma Receives Prestigious $1.5 Million NIH SBIRP Grant to Support Further Development of its Novel Therapy for Acute Pancreatitis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Lamassu Pharma"},{"orgOrder":0,"company":"Altimmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Altimmune Announces Data Presentation on ALT-801","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Peptide","graph2":"Altimmune"},{"orgOrder":0,"company":"Altimmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Altimmune Successfully Completes Multiple Dose Toxicity and Toxicokinetic Studies Of ALT-801 For The Treatment Of NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Peptide","graph2":"Altimmune"},{"orgOrder":0,"company":"Surrozen","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$2.0 million","upfrontCash":"$1.0 million","newsHeadline":"Surrozen Awarded NIH Grant to Support Development of SZN-043","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Surrozen"},{"orgOrder":0,"company":"Ashvattha Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ashvattha Therapeutics to Present Poster on the Use of Novel Hepatocyte Targeted Hydroxyl Dendrimer Therapeutic at The Liver Meeting 2020","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"Ashvattha Therapeutics"},{"orgOrder":0,"company":"Seal Rock Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seal Rock Therapeutics Announces Upcoming Presentations at AASLD's The Liver Meeting\u00ae 2020","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Seal Rock Therapeutics"},{"orgOrder":0,"company":"twoXAR Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"twoXAR Pharmaceuticals Presents Preclinical Data Demonstrating Positive Safety and Tolerability of Two Novel NASH Treatment Candidates","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"twoXAR Pharmaceutical"},{"orgOrder":0,"company":"Seal Rock Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seal Rock Therapeutics Presents Data Highlighting Superior Efficacy of ASK1 Inhibitor, SRT-015, to Selonsertib for NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Seal Rock Therapeutics"},{"orgOrder":0,"company":"HemoShear Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"$470.0 million","upfrontCash":"Undisclosed","newsHeadline":"HemoShear Therapeutics Identifies Novel Drug Target to Treat NASH in Drug Discovery Partnership with Takeda","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"December 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"HemoShear Therapeutics"},{"orgOrder":0,"company":"Enanta Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enanta Pharmaceuticals to Provide Updates on its Research and Development Programs at the 39th Annual J.P. Morgan Healthcare Conference","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Enanta Pharmaceuticals"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Janssen Pharmaceutical","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"Arrowhead Earns $10 Million Option Exercise Fee","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Arrowhead Pharmaceuticals"},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"$170.0 million","upfrontCash":"Undisclosed","newsHeadline":"Dicerna Announces Boehringer Ingelheim\u2019s Acceptance of Candidate for Development Under RNAi Research Collaboration and License Agreement","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Dicerna Pharmaceuticals"},{"orgOrder":0,"company":"Surrozen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Surrozen Presents Data Supporting Potential of SZN-043 at The Liver Biology Conference","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Surrozen"},{"orgOrder":0,"company":"Surrozen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Surrozen Presents Data at 2021 International Liver Conference for Wnt-Modulating Antibody SZN-043","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Surrozen"},{"orgOrder":0,"company":"iECURE","sponsor":"Versant Ventures","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"iECURE Launches With $50 Million Series A Financing to Develop In Vivo Gene Insertion Approaches for Devastating Diseases","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"iECURE"},{"orgOrder":0,"company":"Surrozen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Surrozen Presents Data Supporting Potential of SZN-043 at The Liver Meeting 2021, the Annual Meeting of the American Association for the Study of Liver Diseases","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Surrozen"},{"orgOrder":0,"company":"HemoShear Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"$470.0 million","upfrontCash":"Undisclosed","newsHeadline":"HemoShear Therapeutics Identifies Second Novel Target to Treat NASH Through Successful Collaboration with Takeda","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"November 2021","url1":"","url2":"","graph1":"Undisclosed","graph2":"HemoShear Therapeutics"},{"orgOrder":0,"company":"Ambys Medicines","sponsor":"Third Rock Ventures","pharmaFlowCategory":"D","amount":"$47.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ambys Completes $47 Million Series A Extension to Advance Liver Cell Therapy Platform","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2021","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Ambys Medicines"},{"orgOrder":0,"company":"Miromatrix Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Miromatrix Submits Pre-IND Request to the FDA for Its External Liver Assist Product to Treat Acute Liver Failure","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2021","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Miromatrix Medical"},{"orgOrder":0,"company":"Ambys Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ambys Medicines to Present New Data on Liver Cell Replacement Therapy Platform at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Ambys Medicines"},{"orgOrder":0,"company":"MRM Health","sponsor":"University Hospital of Vall d\u2019Hebron","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MRM Health Reports Preclinical Results Showing a 9-Strain Bacterial Consortium Delays Non-Alcoholic Fatty Liver Disease Progression and Liver Fibrosis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"MRM Health"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Alnylam Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regeneron Genetics Center Discovers Rare Mutations In The CIDEB Gene That Protect Against Liver Disease","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"HemoShear Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"HemoShear Develops New Human Tissue-Based Model of Rare Liver Disease Under Research Collaboration with Takeda","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"August 2022","url1":"","url2":"","graph1":"Undisclosed","graph2":"HemoShear Therapeutics"},{"orgOrder":0,"company":"HemoShear Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"HemoShear Therapeutics Enters into Rare Liver Disease Research Collaboration with Takeda","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"October 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"HemoShear Therapeutics"},{"orgOrder":0,"company":"HemoShear Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"HemoShear Identifies Second Target to Treat NASH for Takeda","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"November 2021","url1":"","url2":"","graph1":"Undisclosed","graph2":"HemoShear Therapeutics"},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"Dong-A ST Co., Ltd.","pharmaFlowCategory":"D","amount":"$37.0 million","upfrontCash":"$22.0 million","newsHeadline":"NeuroBo Pharmaceuticals, Inc. and Dong-A ST Co. Ltd. Announce Strategic Collaboration to License and Develop Portfolio of Dong-A's Cardio-Metabolic Therapies","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"NeuroBo Pharmaceuticals"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Pace Life Sciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Wave BioPharma Presents Research Demonstrating Benefits of Improved Adrulipase Drug Delivery Formulation at AAPS 2022 PharmSci 360","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"First Wave BioPharma"},{"orgOrder":0,"company":"Inipharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inipharm to Present Data on Anti-Fibrotic Effects of Its Development Candidate Targeting HSD17B13 at AASLD\u2019s The Liver Meeting","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Inipharm"},{"orgOrder":0,"company":"Mitobridge","sponsor":"OrsoBio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"OrsoBio Acquires ACMSD Inhibitor Program to Address Mitochondrial Dysfunction from Mitobridge, an Astellas Company","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Undisclosed","graph2":"Mitobridge"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
ACMSD is a key enzyme involved in the de novo synthesis of NAD+, which is critical to mitochondrial function via maintenance of cellular redox state. TLC-065, is being advanced for the treatment of a range of metabolic and inflammatory liver and kidney disorders.
INI-822 a small molecule inhibitor of HSD17B13, data showed favorable drug properties and in vivo changes in lipid metabolism consistent with those observed with protective forms of HSD17B13.
Adrulipase is a recombinant lipase enzyme administered as an oral, non-systemic biologic capsule for the treatment of exocrine pancreatic insufficiency (EPI) associated with cystic fibrosis (CF) and chronic pancreatitis (CP).
DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist, which promotes the release of key gut peptides GLP-1, GIP and PYY, which, in turn, play an important role in glucose metabolism, lipid metabolism and weight loss.
REVEAL-Tx™ combines physiological and computational models of disease to identify novel treatment approaches and select drug candidates in a human-relevant disease context.
Regeneron and Alnylam have developed an siRNA therapeutic candidate targeting CIDEB that could enter clinical stages of development in the next year. The study also found that CIDEB mutations had greater protective associations in individuals with obesity or type 2 diabetes.
Work demonstrated that 9-Strain Live Bacterial Consortium rationally selected gut commensal strains able to improve portal hypertension, insulin signaling and NAFLD activity score at histopathology, prevent fibrosis development in two different in vivo disease models of NASH.
Lead Product(s):
9-Strain Live Bacterial Consortia Therapeutic
AMI-918, an allogeneic, off-the-shelf investigational cell therapy aimed at providing functional liver support in the acute setting, is an important advancement in transforming the treatment of severe liver disease.
The proceeds from this financing will enable the continued expansion of Ambys’s proprietary liver cell therapy production capabilities and the advancement of the company’s lead program, AMI-918, through pre-IND activities.
The request puts Miromatrix on the path for Phase I IND submission and an in-human trial in 2H2022, which will assess the function of a bioengineered liver graft in humans via an external application.
Market Place
News Type
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
